Wall Street Brings Its Financial Engineering to English Football
Chelsea’s new US private-equity owners are betting their knowhow will make the London club more valuable than some of its biggest rivals.
Chelsea’s new US private-equity owners are betting their knowhow will make the London club more valuable than some of its biggest rivals.
Bed Bath & Beyond Inc. executives told suppliers on a video conference call on Thursday that the company would pay them in advance for their merchandise or upon delivery, part of the retailer’s effort to win over skittish manufacturers and put the troubled business back on track.
An index of US leading economic indicators fell in January for a 10th straight month, reflecting declines in consumer expectations and factory orders that underscore risks of a recession.
Asda unveiled plans to give its store employees a double pay rise this year as the UK’s stubborn inflation continues to weigh on living standards.
Luiz Inacio Lula da Silva is only interested in bringing down Brazil’s interest rates, and the government never discussed changing central bank rules or firing its chief Roberto Campos Neto, according to one of the president’s key allies.
Bank of America Corp. and Goldman Sachs Group Inc. economists now see the Federal Reserve extending its interest-rate hiking campaign for longer than expected on the heels of stronger economic data.
The Japanese subsidiary of Sam Bankman-Fried’s failed crypto empire FTX moved a step closer to becoming the first of the group’s businesses to return money to customers.
A senior European banking analyst at Keefe Bruyette & Woods Inc. is leaving his financial markets job behind him to start a new life running a family-owned Bordeaux wine estate.
Russia avoided an economic debacle in the aftermath of President Vladimir Putin’s war in Ukraine, in what was an opening act of a slow-burning crisis that will play out in the years to come.
Moderna Inc. shares lost the most since December after its influenza vaccine yielded mixed results in a final-stage trial, raising questions about the drugmaker’s plan to seek US approval for the messenger RNA-based shot as soon as this year.